Impact of the age expansion of breast screening on screening uptake and screening outcomes among older women in BreastScreen western
CONCLUSIONS: Our study found that age EOS to women aged 70-74 was effective in increasing screening uptake in this age-group but was accompanied by a moderate increase in screening uptake amongst women ≥75 years via self-referral for whom potential benefit of screening may be limited.PMID:33647788 | DOI:10.1016/j.breast.2021.02.006 (Source: Breast)
Source: Breast - March 1, 2021 Category: Cancer & Oncology Authors: Sonia El-Zaemey Wylie Liz Negar Hosseinzadeh Helen Lund Erin Mathieu Nehmat Houssami Source Type: research

Impact of the age expansion of breast screening on screening uptake and screening outcomes among older women in BreastScreen western
CONCLUSIONS: Our study found that age EOS to women aged 70-74 was effective in increasing screening uptake in this age-group but was accompanied by a moderate increase in screening uptake amongst women ≥75 years via self-referral for whom potential benefit of screening may be limited.PMID:33647788 | DOI:10.1016/j.breast.2021.02.006 (Source: Breast)
Source: Breast - March 1, 2021 Category: Cancer & Oncology Authors: Sonia El-Zaemey Wylie Liz Negar Hosseinzadeh Helen Lund Erin Mathieu Nehmat Houssami Source Type: research

Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics
Breast. 2021 Feb 17;56:78-87. doi: 10.1016/j.breast.2021.02.007. Online ahead of print.ABSTRACTThe tumour microenvironment has been shown to be a valuable source of prognostic information for different cancer types. This holds in particular for triple negative breast cancer (TNBC), a breast cancer subtype for which currently no prognostic biomarkers are established. Although different methods to assess tumour infiltrating lymphocytes (TILs) have been published, it remains unclear which method (marker, region) yields the most optimal prognostic information. In addition, to date, no objective TILs assessment methods are avai...
Source: Breast - February 28, 2021 Category: Cancer & Oncology Authors: Maschenka Ca Balkenhol Francesco Ciompi Żaneta Świderska-Chadaj Rob van de Loo Milad Intezar Irene Otte-H öller Daan Geijs Johannes Lotz Nick Weiss Thomas de Bel Geert Litjens Peter Bult Jeroen Awm van der Laak Source Type: research

Pregnancy associated breast cancer (PABC): Report from a gestational cancer registry from a tertiary cancer care centre, India
CONCLUSION: Data from the first Indian PABC registry showed that the majority had delayed diagnosis and aggressive features(TNBC, higher grade). Treatment was feasible in majority and stage matched outcomes were comparable to non-PABCs.PMID:33640524 | DOI:10.1016/j.breast.2021.02.005 (Source: Breast)
Source: Breast - February 28, 2021 Category: Cancer & Oncology Authors: Jyoti Bajpai Vijay Simha T S Shylasree Rajeev Sarin Reema Pathak Palak Popat Smruti Mokal Sonal Dandekar Jaya Ghosh Neeta Nair Seema Gulia Sushmita Rath Shalaka Joshi Tabassum Wadasadawala Tanuja Sheth Vani Parmar S D Banavali R A Badwe Sudeep Gupta Source Type: research

Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics
Breast. 2021 Feb 17;56:78-87. doi: 10.1016/j.breast.2021.02.007. Online ahead of print.ABSTRACTThe tumour microenvironment has been shown to be a valuable source of prognostic information for different cancer types. This holds in particular for triple negative breast cancer (TNBC), a breast cancer subtype for which currently no prognostic biomarkers are established. Although different methods to assess tumour infiltrating lymphocytes (TILs) have been published, it remains unclear which method (marker, region) yields the most optimal prognostic information. In addition, to date, no objective TILs assessment methods are avai...
Source: Breast - February 28, 2021 Category: Cancer & Oncology Authors: Maschenka Ca Balkenhol Francesco Ciompi Żaneta Świderska-Chadaj Rob van de Loo Milad Intezar Irene Otte-H öller Daan Geijs Johannes Lotz Nick Weiss Thomas de Bel Geert Litjens Peter Bult Jeroen Awm van der Laak Source Type: research

Pregnancy associated breast cancer (PABC): Report from a gestational cancer registry from a tertiary cancer care centre, India
CONCLUSION: Data from the first Indian PABC registry showed that the majority had delayed diagnosis and aggressive features(TNBC, higher grade). Treatment was feasible in majority and stage matched outcomes were comparable to non-PABCs.PMID:33640524 | DOI:10.1016/j.breast.2021.02.005 (Source: Breast)
Source: Breast - February 28, 2021 Category: Cancer & Oncology Authors: Jyoti Bajpai Vijay Simha T S Shylasree Rajeev Sarin Reema Pathak Palak Popat Smruti Mokal Sonal Dandekar Jaya Ghosh Neeta Nair Seema Gulia Sushmita Rath Shalaka Joshi Tabassum Wadasadawala Tanuja Sheth Vani Parmar S D Banavali R A Badwe Sudeep Gupta Source Type: research

Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study
CONCLUSIONS: FN incidences were above 20% in the 3 regimens, with TC showing the highest. RDI was maintained at a high level in both visiting and non-visiting groups. Patient-related risk factors were age and pretreatment ANC.PMID:33631458 | DOI:10.1016/j.breast.2021.01.005 (Source: Breast)
Source: Breast - February 25, 2021 Category: Cancer & Oncology Authors: Takashi Ishikawa Kentaro Sakamaki Kazutaka Narui Hideki Nishimura Takafumi Sangai Kentaro Tamaki Yoshie Hasegawa Ken-Ichi Watanabe Nobuyasu Suganuma Shintaro Michishita Sadatoshi Sugae Tomohiko Aihara Koichiro Tsugawa Hirose Kaise Naruto Taira Hirofumi Mu Source Type: research

Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study
CONCLUSIONS: FN incidences were above 20% in the 3 regimens, with TC showing the highest. RDI was maintained at a high level in both visiting and non-visiting groups. Patient-related risk factors were age and pretreatment ANC.PMID:33631458 | DOI:10.1016/j.breast.2021.01.005 (Source: Breast)
Source: Breast - February 25, 2021 Category: Cancer & Oncology Authors: Takashi Ishikawa Kentaro Sakamaki Kazutaka Narui Hideki Nishimura Takafumi Sangai Kentaro Tamaki Yoshie Hasegawa Ken-Ichi Watanabe Nobuyasu Suganuma Shintaro Michishita Sadatoshi Sugae Tomohiko Aihara Koichiro Tsugawa Hirose Kaise Naruto Taira Hirofumi Mu Source Type: research

Prospective cohort study of febrile neutropenia in breast cancer patients administered with neoadjuvant and adjuvant chemotherapies: CSPOR-BC FN study
CONCLUSIONS: FN incidences were above 20% in the 3 regimens, with TC showing the highest. RDI was maintained at a high level in both visiting and non-visiting groups. Patient-related risk factors were age and pretreatment ANC.PMID:33631458 | DOI:10.1016/j.breast.2021.01.005 (Source: Breast)
Source: Breast - February 25, 2021 Category: Cancer & Oncology Authors: Takashi Ishikawa Kentaro Sakamaki Kazutaka Narui Hideki Nishimura Takafumi Sangai Kentaro Tamaki Yoshie Hasegawa Ken-Ichi Watanabe Nobuyasu Suganuma Shintaro Michishita Sadatoshi Sugae Tomohiko Aihara Koichiro Tsugawa Hirose Kaise Naruto Taira Hirofumi Mu Source Type: research

Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability
Breast. 2021 Feb 10;56:61-69. doi: 10.1016/j.breast.2021.02.003. Online ahead of print.ABSTRACTThe uptake of contralateral prophylactic mastectomy (CPM) has increased steadily over the last twenty years in women of all age groups and breast cancer stages. Since contralateral breast cancer is relatively rare and the breast cancer guidelines only recommend CPM in a small subset of patients with breast cancer, the drivers of this trend are unknown. This review aims to evaluate the evidence for and acceptability of CPM, data on patient rationales for choosing CPM, and some of the factors that might impact patient preferences. ...
Source: Breast - February 23, 2021 Category: Cancer & Oncology Authors: Josien C C Scheepens Laura van 't Veer Laura Esserman Jeff Belkora Rita A Mukhtar Source Type: research

Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability
Breast. 2021 Feb 10;56:61-69. doi: 10.1016/j.breast.2021.02.003. Online ahead of print.ABSTRACTThe uptake of contralateral prophylactic mastectomy (CPM) has increased steadily over the last twenty years in women of all age groups and breast cancer stages. Since contralateral breast cancer is relatively rare and the breast cancer guidelines only recommend CPM in a small subset of patients with breast cancer, the drivers of this trend are unknown. This review aims to evaluate the evidence for and acceptability of CPM, data on patient rationales for choosing CPM, and some of the factors that might impact patient preferences. ...
Source: Breast - February 23, 2021 Category: Cancer & Oncology Authors: Josien C C Scheepens Laura van 't Veer Laura Esserman Jeff Belkora Rita A Mukhtar Source Type: research

Can supplementary contrast-enhanced MRI of the breast avoid needle biopsies in suspicious microcalcifications seen on mammography? A systematic review and meta-analysis
Breast. 2021 Feb 15;56:53-60. doi: 10.1016/j.breast.2021.02.002. Online ahead of print.ABSTRACTPURPOSE: To analyze the rate of potentially avoidable needle biopsies in mammographically suspicious calcifications if supplementary Contrast-Enhanced MRI (CE-MRI) is negative.METHODS: Using predefined criteria, a systematic review was performed. Studies investigating the use of supplemental CE-MRI in the setting of mammographically suspicious calcifications undergoing stereotactic biopsy and published between 2000 and 2020 were eligible. Two reviewers extracted study characteristics and true positives (TP), false positives, true...
Source: Breast - February 22, 2021 Category: Cancer & Oncology Authors: Barbara J Fueger Paola Clauser Panagiotis Kapetas Nina P ötsch Thomas H Helbich Pascal A T Baltzer Source Type: research

Can supplementary contrast-enhanced MRI of the breast avoid needle biopsies in suspicious microcalcifications seen on mammography? A systematic review and meta-analysis
Breast. 2021 Feb 15;56:53-60. doi: 10.1016/j.breast.2021.02.002. Online ahead of print.ABSTRACTPURPOSE: To analyze the rate of potentially avoidable needle biopsies in mammographically suspicious calcifications if supplementary Contrast-Enhanced MRI (CE-MRI) is negative.METHODS: Using predefined criteria, a systematic review was performed. Studies investigating the use of supplemental CE-MRI in the setting of mammographically suspicious calcifications undergoing stereotactic biopsy and published between 2000 and 2020 were eligible. Two reviewers extracted study characteristics and true positives (TP), false positives, true...
Source: Breast - February 22, 2021 Category: Cancer & Oncology Authors: Barbara J Fueger Paola Clauser Panagiotis Kapetas Nina P ötsch Thomas H Helbich Pascal A T Baltzer Source Type: research

A multidisciplinary view of mastectomy and breast reconstruction: Understanding the challenges
Breast. 2021 Feb 10;56:42-52. doi: 10.1016/j.breast.2021.02.004. Online ahead of print.ABSTRACTThe current review paper was written in collaboration with breast cancer surgeons from the European Breast Cancer Research Association of Surgical Trialists (EUBREAST), a breast pathologist from the Danish Breast Cancer Group (DBCG), and representatives from the European SocieTy for Radiotherapy & Oncology (ESTRO) breast cancer course. Herein we summarize the different mastectomies and reconstruction procedures and define high-risk anatomical areas for breast cancer recurrences, to further specify the challenges in the surgic...
Source: Breast - February 21, 2021 Category: Cancer & Oncology Authors: Orit Kaidar-Person Birgitte V Offersen Liesbeth J Boersma Dirk de Ruysscher Trine Tramm Thorsten K ühn Oreste Gentilini Zolt án Mátrai Philip Poortmans Source Type: research

Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer
Breast. 2021 Jan 15;56:35-41. doi: 10.1016/j.breast.2021.01.001. Online ahead of print.ABSTRACTNeoadjuvant chemotherapy (NAC) is an optimal option in early breast cancer, but in ER-positive/HER2-negative (luminal) is still controversial, although a survival benefit has recently been observed when a histological response by Symmans' method type 0 or I is achieved. The 21-gene Oncotype DX Breast Recurrence Score® assay (Oncotype DX®) is a validated test to assess the survival benefit of adjuvant chemotherapy in these patients but its role in the neoadjuvant setting is less established. We analyzed the results of the ...
Source: Breast - February 18, 2021 Category: Cancer & Oncology Authors: Serafin Morales Murillo Ariadna Gasol Cudos Joel Veas Rodriguez Carles Canosa Morales Jordi Mel é Olivé Felip Vilardell Villellas Douglas Rene Sanchez Guzman Edelmiro Iglesias Mart ínez Antonieta Salud Salvia Source Type: research

Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - A systematic review and meta-analysis
Breast. 2021 Feb 4;56:26-34. doi: 10.1016/j.breast.2021.02.001. Online ahead of print.ABSTRACTBACKGROUND: The non-inferiority of combined breast conservation surgery (BCS) and radiotherapy (breast conservation therapy or BCT) compared to mastectomy in sporadic breast cancer cases is well recognised. Uncertainty remains regarding optimal surgical practice in BRCA mutation carriers.AIMS: To evaluate the oncological safety of combined BCT versus mastectomy in BRCA mutation carriers following breast cancer diagnosis.METHODS: A systematic review was performed as per PRISMA and MOOSE guidelines. Observational studies comparing B...
Source: Breast - February 14, 2021 Category: Cancer & Oncology Authors: M G Davey C M Davey É J Ryan A J Lowery M J Kerin Source Type: research

Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program
CONCLUSION: The duration of each previous PFS is a major prognostic factor for OS in mTNBC patients receiving third- or fourth-line chemotherapy. The clinical utility of nomograms including this information was not demonstrated.PMID:33561617 | PMC:PMC7873471 | DOI:10.1016/j.breast.2021.01.006 (Source: Breast)
Source: Breast - February 9, 2021 Category: Cancer & Oncology Authors: Luc Cabel Matthieu Carton Barbara Pistilli Florence Dalenc Laurence Vanlemnens Christelle Levy William Jacot Michel Debled Agnes Loeb Audrey Hennequin Thibault De la Motte Rouge Lilian Laborde Carine Laurent E Chamorey Damien Parent Thierry Petit Marie-An Source Type: research

Breast cancer surgery with augmented reality
CONCLUSION: Breast cancer conservative guided surgery with augmented reality can pave the way for a digital non-invasive method for intra-operative tumor localization.PMID:33548617 | DOI:10.1016/j.breast.2021.01.004 (Source: Breast)
Source: Breast - February 6, 2021 Category: Cancer & Oncology Authors: Pedro F Gouveia Joana Costa Pedro Morgado Ronald Kates David Pinto Carlos Mavioso Jo ão Anacleto Marta Martinho Daniel Sim ões Lopes Arlindo R Ferreira Vasileios Vavourakis Myrianthi Hadjicharalambous Marco A Silva Nickolas Papanikolaou Celeste Alves Fa Source Type: research

Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - A systematic review and meta-analysis.
in MJ Abstract BACKGROUND: The non-inferiority of combined breast conservation surgery (BCS) and radiotherapy (breast conservation therapy or BCT) compared to mastectomy in sporadic breast cancer cases is well recognised. Uncertainty remains regarding optimal surgical practice in BRCA mutation carriers. AIMS: To evaluate the oncological safety of combined BCT versus mastectomy in BRCA mutation carriers following breast cancer diagnosis. METHODS: A systematic review was performed as per PRISMA and MOOSE guidelines. Observational studies comparing BCS and mastectomy in BRCA carriers were identified. Dichot...
Source: Breast - February 4, 2021 Category: Cancer & Oncology Authors: Davey MG, Davey CM, Ryan ÉJ, Lowery AJ, Kerin MJ Tags: Breast Source Type: research

Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program.
CONCLUSION: The duration of each previous PFS is a major prognostic factor for OS in mTNBC patients receiving third- or fourth-line chemotherapy. The clinical utility of nomograms including this information was not demonstrated. PMID: 33561617 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - January 30, 2021 Category: Cancer & Oncology Authors: Cabel L, Carton M, Pistilli B, Dalenc F, Vanlemnens L, Levy C, Jacot W, Debled M, Loeb A, Hennequin A, De la Motte Rouge T, Laborde L, Laurent C, Chamorey E, Parent D, Petit T, Mouret-Reynier MA, Campone M, Perrocheau G, Labreveux C, Bachelot T, Robain M, Tags: Breast Source Type: research

Breast cancer surgery with augmented reality.
CONCLUSION: Breast cancer conservative guided surgery with augmented reality can pave the way for a digital non-invasive method for intra-operative tumor localization. PMID: 33548617 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - January 27, 2021 Category: Cancer & Oncology Authors: Gouveia PF, Costa J, Morgado P, Kates R, Pinto D, Mavioso C, Anacleto J, Martinho M, Lopes DS, Ferreira AR, Vavourakis V, Hadjicharalambous M, Silva MA, Papanikolaou N, Alves C, Cardoso F, Cardoso MJ Tags: Breast Source Type: research

Impact of radiation dose on complications among women with breast cancer who underwent breast reconstruction and post-mastectomy radiotherapy: A multi-institutional validation study.
This study aimed to validate previous findings regarding the impact of radiation dose on complications among women with breast cancer using a multi-center dataset. METHODS: Fifteen institutions participated, and women with breast cancer who received radiotherapy after either autologous or prosthetic breast reconstruction were included. The primary endpoint was major post-radiation therapy complications requiring re-operation for explantation, flap failure, or bleeding control. RESULTS: In total, 314 patients were included. Radiotherapy was performed using both conventional fractionation and hypofractionation in v...
Source: Breast - January 20, 2021 Category: Cancer & Oncology Authors: Chung SY, Chang JS, Shin KH, Kim JH, Park W, Kim H, Kim K, Lee IJ, Yoon WS, Cha J, Lee KC, Kim JH, Choi JH, Ahn SJ, Ha B, Lee SY, Lee DS, Lee J, Shin SO, Lee SW, Choi J, Kim MY, Kim YJ, Im JH, Suh CO, Kim YB Tags: Breast Source Type: research

Experiences, expectations and preferences regarding MRI and mammography as breast cancer screening tools in women at familial risk.
In this study, experiences, expectations and preferences for MRI and mammography were evaluated among women undergoing screening with MRI and/or mammography in the randomized FaMRIsc trial. METHODS: A 17-item questionnaire was sent to 412 women in the FaMRIsc trial. Participants were aged 30-55 years, had a ≥20% cumulative lifetime risk, but no BRCA1/2 or TP53 gene variant, and were screened outside the population-based screening program. Women received annual mammography (mammography-group), or annual MRI and biennial mammography (MRI-group). We asked whether women trust the screening outcome, what they consider a...
Source: Breast - January 18, 2021 Category: Cancer & Oncology Authors: Geuzinge HA, Heijnsdijk EAM, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MMA, FaMRIsc study group Tags: Breast Source Type: research

Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany".
Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". Breast. 2021 Jan 04;: Authors: Schneeweiss A, Ettl J, Lüftner D, Beckmann MW, Belleville E, Fasching PA, Fehm TN, Geberth M, Häberle L, Hadji P, Hartkopf AD, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg HC, Kurbacher CM, Klein E, Lux MP, Müller V, Nabieva N, Overkamp F, ...
Source: Breast - January 4, 2021 Category: Cancer & Oncology Authors: Schneeweiss A, Ettl J, Lüftner D, Beckmann MW, Belleville E, Fasching PA, Fehm TN, Geberth M, Häberle L, Hadji P, Hartkopf AD, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg HC, Kurbacher CM, Klein E, Lux MP, Müller V, Nabieva N, Overkamp F, T Tags: Breast Source Type: research

The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study.
Abstract BACKGROUND: The potential benefit of additional breast cancer screening examinations in moderate risk patients (patients with a history of breast cancer in one or two family members) remains unclear. METHODS: A large population-based case-control study on breast cancer in postmenopausal women in Germany recruited 2002-2005 (3813 cases and 7341 age-matched controls) was used to assess the association of family history with breast cancer risk. Analysis of family history, participation in screening procedures, and tumor size regarding prognosis in patients was based on follow-up data until 2015. RE...
Source: Breast - December 24, 2020 Category: Cancer & Oncology Authors: Seiffert K, Thoene K, Eulenburg CZ, Behrens S, Schmalfeldt B, Becher H, Chang-Claude J, Witzel I Tags: Breast Source Type: research

Acute toxicity and health-related quality of life after accelerated whole breast irradiation in 5 fractions with simultaneous integrated boost.
We report on acute toxicity after whole-breast irradiation with a simultaneous integrated boost in 5 fractions over 10-12 days. MATERIAL AND METHODS: Acute toxicity and health-related quality of life (HRQoL) of 200 patients, randomized between a 15- or 5-fractions schedule, were collected, using the CTCAE toxicity scoring system, the Multidimensional Fatigue Inventory, EORTC QLQ-C30 and BR23 and the BREAST-Q questionnaire. The prescribed dose to the breast was either 15∗2.67 Gy (40.05 Gy) or 5∗5.7 Gy (28.5 Gy). 90% of patients received a SIB to a cumulative dose of 46.8 Gy (15&lo...
Source: Breast - December 24, 2020 Category: Cancer & Oncology Authors: Van Hulle H, Vakaet V, Monten C, Deseyne P, Schoepen M, Colman C, Paelinck L, Van Greveling A, Post G, Speleers B, Vandecasteele K, Mareel M, De Neve W, Veldeman L Tags: Breast Source Type: research

Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe.
, Cardoso F Abstract People with metastatic breast cancer face many challenges and disparities in obtaining optimal cancer care. These challenges are accentuated in underserved patient populations across Europe, who are less likely to receive quality healthcare for reasons including socioeconomic inequalities, educational or cultural status, or geographic location. While there are many local and national initiatives targeted to address these challenges, there remains a need to reduce disparities and improve access to healthcare to improve outcomes, with a focus on multidisciplinary stakeholder engagement. In Octob...
Source: Breast - December 13, 2020 Category: Cancer & Oncology Authors: Vrdoljak E, Gligorov J, Wierinck L, Conte P, De Grève J, Meunier F, Palmieri C, Travado L, Walker A, Wiseman T, Wuerstlein R, Alba E, Biurrún C, D'Antona R, Sola-Morales O, Ubaysi C, Ventura R, Cardoso F Tags: Breast Source Type: research

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer.
Abstract Cell-cycle abnormalities are common in estrogen receptor- and/or progesterone receptor-positive, and HER2-non-overexpressing (HR+/HER2-) breast cancer, and have long been considered potential therapeutic targets. Cyclin-dependent kinase (CDK) 4/6 inhibitors have dramatically changed the therapeutic management of HR+/HER2-advanced breast cancer by prolonging progression-free and overall survival when given in combination with endocrine therapy. In this article, available data from PALLAS and monarchE trials regarding the efficacy and toxicity of adjuvant combined therapy with CDK 4/6 inhibitors and endocin...
Source: Breast - December 13, 2020 Category: Cancer & Oncology Authors: Di Cosimo S, Porcu L, Cardoso F Tags: Breast Source Type: research

Mammographic sensitivity as a function of tumor size: A novel estimation based on population-based screening data.
CONCLUSION: Derived from aggregated breast screening outcomes data, our model's estimation of sensitivity as a function of tumor size may provide a better representation of data observed in screening programs than other models. PMID: 33348148 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - December 9, 2020 Category: Cancer & Oncology Authors: Wang J, Gottschal P, Ding L, Veldhuizen DAV, Lu W, Houssami N, Greuter MJW, de Bock GH Tags: Breast Source Type: research

Randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
CONCLUSIONS: Intravenous administration of low-dose nab-PTX at 180 mg/m2 q3w may be the optimal therapy with meaningful efficacy and favorable toxicity in patients with MBC. PMID: 33341707 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - December 9, 2020 Category: Cancer & Oncology Authors: Tsurutani J, Hara F, Kitada M, Takahashi M, Kikawa Y, Kato H, Sakata E, Naito Y, Hasegawa Y, Saito T, Iwasa T, Taira N, Takashima T, Kashiwabara K, Aihara T, Mukai H Tags: Breast Source Type: research

Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?
CONCLUSION: While the overall estimated probability of LR within 5 years after WBHF-IMRT without boost is good (2.2%), molecular subtypes have a strong impact, despite MAb therapy in Her2+ patients, and CT for TNBC patients, and could be used as a parameter in deciding the boost prescription. PMID: 33326894 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - December 9, 2020 Category: Cancer & Oncology Authors: Fodor A, Brombin C, Mangili P, Borroni F, Pasetti M, Tummineri R, Zerbetto F, Longobardi B, Perna L, Dell'Oca I, Deantoni CL, Deli AM, Chiara A, Broggi S, Castriconi R, Esposito PG, Slim N, Passoni P, Baroni S, Villa SL, Rancoita PMV, Fiorino C, Del Vecch Tags: Breast Source Type: research

Artificial intelligence (AI) in breast cancer care - Leveraging multidisciplinary skills to improve care.
ssi B PMID: 33308879 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - December 9, 2020 Category: Cancer & Oncology Authors: Cardoso MJ, Houssami N, Pozzi G, Séroussi B Tags: Breast Source Type: research

Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China.
Abstract PURPOSE: To characterize the incidence, risk factors and survival of patients with brain metastases at initial diagnosis of metastatic breast cancer (MBC) in China. METHODS: The China National Cancer Center database was used to identify 2087 MBC patients diagnosed between 2003 and 2015. Clinicopathological features, treatment and survival information were extracted. Multivariable logistic and Cox regression were performed to determine factors predictive of brain metastases at MBC diagnosis and survival, respectively. RESULTS: Brain metastases occurred in ninety patients (4.3%) at MBC diagnosis, ...
Source: Breast - December 4, 2020 Category: Cancer & Oncology Authors: Li Y, Li Q, Mo H, Guan X, Lin S, Wang Z, Chen Y, Zhang Y, Zhang D, Chen S, Cai R, Wang J, Luo Y, Fan Y, Yuan P, Zhang P, Li Q, Ma F, Xu B Tags: Breast Source Type: research

Residual breast tissue after robot-assisted nipple sparing mastectomy.
CONCLUSIONS: In this cadaveric study, RNSM is feasible leaving minimal RBT on the mastectomy flap. The most common location for RBT is in the periareolar location consistent with previous published findings after open NSM. Clinical studies are underway to evaluate the safety of RNSM. PMID: 33310481 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - December 3, 2020 Category: Cancer & Oncology Authors: Park KU, Tozbikian GH, Ferry D, Tsung A, Chetta M, Schulz S, Skoracki R Tags: Breast Source Type: research

Hypofractionated versus conventional fractionated radiotherapy for breast cancer in patients with reconstructed breast: Toxicity analysis.
CONCLUSIONS: There was no significant difference in the occurrence of any or major breast-related complications between the two different fractionation regimens, even in patients with mastectomy. Hypofractionated RT may be used comparable to conventional fractionated RT in terms of breast-related complications in reconstructed breast cancer patients. The prospective randomized trial would be necessary to clarify this issue. PMID: 33316582 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - December 1, 2020 Category: Cancer & Oncology Authors: Kim DY, Park E, Heo CY, Jin US, Kim EK, Han W, Shin KH, Kim IA Tags: Breast Source Type: research

Impact of body mass index on overall survival in patients with metastatic breast cancer.
CONCLUSION: Overweight and obesity are not associated with poorer outcomes in women with metastatic disease, while underweight appears as an independent adverse prognostic factor. PMID: 33307392 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - December 1, 2020 Category: Cancer & Oncology Authors: Saleh K, Carton M, Dieras V, Heudel PE, Brain E, D'Hondt V, Mailliez A, Patsouris A, Mouret-Reynier MA, Goncalves A, Ferrero JM, Petit T, Emile G, Uwer L, Debled M, Dalenc F, Jouannaud C, Ladoire S, Leheurteur M, Cottu P, Veron L, Savignoni A, Courtinard Tags: Breast Source Type: research

Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis.
This study included 8524 patients, 1987 (23.3%) had low RS, 5059 (59.4%) had intermediate RS, and 1478 (17.3%) had high RS. Chemotherapy was administrated in 2.0%, 8.6%, and 51.2% for low, intermediate, and high RS cohorts, respectively (P 
Source: Breast - November 28, 2020 Category: Cancer & Oncology Authors: Zhou P, Zhang WW, Bao Y, Wang J, Lian CL, He ZY, Wu SG Tags: Breast Source Type: research

Complete response of leptomeningeal carcinomatosis secondary to breast cancer.
Abstract Leptomeningeal carcinomatosis (LC) is an unmet medical need associated with death in 4-6 weeks without treatment, delayed by 4 months in some patients with favorable prognosis and aggressive multimodal therapy. Unfortunately, most clinical trials excluded patients with LC, and the best management remains unknown. Here we present the first report of a LC secondary to HR positive breast cancer with a complete response to CDK4/6 inhibitors abemaciclib, letrozole and hippocampal-avoidance whole-brain radiotherapy. PMID: 33278649 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 28, 2020 Category: Cancer & Oncology Authors: Troussier I, Canova C, Klausner G Tags: Breast Source Type: research

Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor-Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems.
Abstract After more than two decades of intensive research, tremendous progress has been achieved in the management of Human Epidermal Receptor-2 overexpressing (Her2+) Early Breast Cancer (EBC). In the latest years, major clinical trials have explored the neoadjuvant scenario, in addition to the prognostic role of pathologic complete response (pCR) and the possibility of a 'tumor biology-driven' patient selection provided by the assessment pathologic response. However, the introduction of new agents has been a major burden for financially-constrained healthcare systems-which includes those from most emerging mark...
Source: Breast - November 27, 2020 Category: Cancer & Oncology Authors: Mano MS Tags: Breast Source Type: research

Prognosis of HER2-positive pregnancy-associated breast cancer: Analysis from the French CALG (Cancer Associ é à La Grossesse) network.
CONCLUSION: This matched case-control study implies that patients with HER2-positive BCP still have a poorer prognosis than non-pregnant HER-positive patients. PMID: 33271423 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 26, 2020 Category: Cancer & Oncology Authors: Boudy AS, Ferrier C, Selleret L, Zilberman S, Arfi A, Sussfeld J, Gligorov J, Richard S, Bendifallah S, Chabbert-Buffet N, Touboul C, Daraï E Tags: Breast Source Type: research

Reply to Letter to Editor: "HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?"
Reply to Letter to Editor: "HER2 positivity in patients with estrogen receptor (ER) positive breast cancer: Is it really prognostic?" Breast. 2020 Nov 21;: Authors: Li S, Chen X PMID: 33262007 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 21, 2020 Category: Cancer & Oncology Authors: Li S, Chen X Tags: Breast Source Type: research

Older women's experience with breast cancer treatment: A systematic review of qualitative literature.
CONCLUSION: Older women with breast cancer have unique challenges specific to each phase of their treatment journey. Older women may benefit from proactive treatment discussions with health care providers to address their specific needs, individualize care, and assist with cancer care navigation. PMID: 33242756 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 16, 2020 Category: Cancer & Oncology Authors: Angarita FA, Zhang Y, Elmi M, Look Hong NJ Tags: Breast Source Type: research

Palbociclib combined with endocrine therapy in heavily pretreated HR+/HER2- advanced breast cancer patients: Results from the compassionate use program in Spain (PALBOCOMP).
This study evaluated efficacy and safety of palbociclib, a CDK4/6 inhibitor, in heavily-pretreated hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) patients during the compassionate use program in Spain from February 2015 to November 2017. PATIENTS AND METHODS: Patient data were collected retrospectively from 35 hospitals in Spain. Patients with HR+/HER2- mBC who had progressed on ≥4 treatments for advanced disease were eligible. RESULTS: A total of 219 patients received palbociclib in combination with aromatase inhibitors (110; 50.2%), ...
Source: Breast - November 13, 2020 Category: Cancer & Oncology Authors: Manso L, Hernando C, Galán M, Oliveira M, Cabrera MA, Bratos R, Rodríguez CA, Ruiz-Borrego M, Blanch S, Llombart-Cussac A, Delgado-Mingorance JI, Álvarez-Busto I, Gallegos I, González-Cortijo L, Morales S, Aguirre E, Hernando BA, Ballesteros A, Alés- Tags: Breast Source Type: research

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer.
CONCLUSION: In a non-selected population of patients with HR + HER2- ABC, the efficacy and safety data are strikingly similar to those previously reported. PMID: 33242757 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 13, 2020 Category: Cancer & Oncology Authors: Porte B, Carton M, Lerebours F, Brain E, Loirat D, Haroun L, Bellesoeur A, Bach Hamba S, Kirova Y, Cottu P Tags: Breast Source Type: research

Breast ultrasound in breast cancer surveillance; incremental cancers found at what cost?
CONCLUSIONS: Breast US has a sensitivity of 44.1% and detected seven recurrences that were mammographically occult. Breast US has a similar PPV to mammography in surveillance. Breast US generated considerable biopsy rates and costs. Survival analysis was not able to detect any benefit of US detected cases of recurrence. PMID: 33242753 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 11, 2020 Category: Cancer & Oncology Authors: Bromley L, Xu J, Loh SW, Chew G, Lau E, Yeo B Tags: Breast Source Type: research

A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting.
Abstract PURPOSE: Despite triple antiemetic therapy use for breast cancer patients receiving emetogenic chemotherapy, nausea remains a clinical challenge. We evaluated adding olanzapine (5 mg) to triple therapy on nausea control in patients at high personal risk of chemotherapy-induced nausea and vomiting (CINV). METHODS: This multi-centre, placebo-controlled, double-blind trial randomized breast cancer patients scheduled to receive neo/adjuvant chemotherapy with anthracycline-cyclophosphamide or platinum-based chemotherapy to olanzapine (5 mg, days 1-4) or placebo. Primary endpoint was frequency of...
Source: Breast - November 10, 2020 Category: Cancer & Oncology Authors: Clemons M, Dranitsaris G, Sienkiewicz M, Sehdev S, Ng T, Robinson A, Mates M, Hsu T, McGee S, Freedman O, Kumar V, Fergusson D, Hutton B, Vandermeer L, Hilton J Tags: Breast Source Type: research

Response to: Intrinsic subtype distribution should vary according to institutions.
PMID: 33221060 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 10, 2020 Category: Cancer & Oncology Authors: Fischer Maranta A, Ruhstaller T Tags: Breast Source Type: research

Intrinsic subtype distribution should vary according to institutions.
PMID: 33199215 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 10, 2020 Category: Cancer & Oncology Authors: Horimoto Y, Tanabe M Tags: Breast Source Type: research

Individualized-thresholding Shear Wave Elastography combined with clinical factors improves specificity in discriminating breast masses.
CONCLUSIONS: The false-positive rate can be significantly reduced when applying two Emean cutoffs based on lesion size and depth. Moreover, the combination of age, Emean with two cutoffs and BI-RADS can further reduce the false negatives and false positives. Overall, this multifactorial analysis improves the specificity of ultrasound while maintaining a high sensitivity. PMID: 33188991 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 4, 2020 Category: Cancer & Oncology Authors: Gu J, Polley EC, Ternifi R, Nayak R, Boughey JC, Fazzio RT, Fatemi M, Alizad A Tags: Breast Source Type: research

Neoadjuvant chemotherapy and HER2 dual blockade including biosimilar trastuzumab (SB3) for HER2-positive early breast cancer: Population based real world data from the Danish Breast Cancer Group (DBCG).
CONCLUSION: Real world data on dual blockade with SB3 and pertuzumab in combination with NACT in a nationwide population-based study show a pCR rate comparable to that seen in previous clinical studies. PMID: 33186804 [PubMed - as supplied by publisher] (Source: Breast)
Source: Breast - November 3, 2020 Category: Cancer & Oncology Authors: Berg T, Jensen MB, Jakobsen EH, Al-Rawi S, Kenholm J, Andersson M Tags: Breast Source Type: research